Please login to the form below

Not currently logged in
Email:
Password:

generic drugs

This page shows the latest generic drugs news and features for those working in and with pharma, biotech and healthcare.

US government shutdown leaves FDA running on empty

US government shutdown leaves FDA running on empty

It has a month of funding left for drugs, a two to three months for medical devices and a couple of months for generic drugs, all of which are financed using

Latest news

  • Drug pricing is pharma’s top concern in 2019 Drug pricing is pharma’s top concern in 2019

    The average price increase this year was about 6.3% and includes branded as well as generic drugs, according to GlobalData, which notes that “both democrats and republicans have reacted strongly ... to these latest increases and it could be an

  • GSK and Pfizer to create combined consumer health titan GSK and Pfizer to create combined consumer health titan

    Spin-out will allow GSK to focus on prescription drugs and vaccines. ... In effect this is consumer brand management of largely generic drugs.

  • Brexit contributes to surge in generic drug prices Brexit contributes to surge in generic drug prices

    Calls for government to protect pharmacies. Shortages are driving up prices of key generic drugs in the UK, which pharmacy representatives say is being caused by Brexit and a handful of ... Others drugs seeing prices rises in 2018 include Allopurinol,

  • Reference price bill tabled in US House and Senate Reference price bill tabled in US House and Senate

    approve generic versions of drugs if manufacturers insist on maintaining process above that level. ... savings for several other drugs including Pfizer’s hormone replacement therapy Premarin (conjugated oestrogens),   Merck &Co’s Januvia

  • US insurers can peg access to ICER value reviews US insurers can peg access to ICER value reviews

    The adoption of ICER guidance is part of an array of approaches taken to limit drug costs by the PBM, along with encouraging the use of generic substitution for brandname drugs, ... Sanofi/Regeneron, GlaxoSmithKline’s severe asthma therapy Nucala

More from news
Approximately 3 fully matching, plus 259 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    The main drivers of revenue for Roche are well-established, standard-of-care blockbuster oncology drugs including Rituxan, Herceptin and Avastin. ... Roche will likely take the biggest loss in Europe, where nationalised healthcare systems are keen to

  • Deal Watch June 2016 Deal Watch June 2016

    The three deals with Mayne Pharma, Impax Laboratories and Dr Reddy's, for a combined value of over $1.5bn, cover portfolios of marketed and approved generic drugs, drugs currently pending ... 8 generic drugs - filed ANDAs pending approval and an approved

  • Cost containment and the German market Cost containment and the German market

    They represent an established instrument of cost control, especially in the generic segment, as 93% of all drugs under rebate contract are generics. ... Focusing on patented drugs, the price difference to the generic segment is significant.

  • Deal Watch February 2016 Deal Watch February 2016

    Licensor Acquired/Licensee Acquirer. Product/Technology. Deal Type. Headline ($m). Meda/Mylan. portfolio of branded, OTC and generic drugs.

  • Social media and inflation penalties for generic drugs Social media and inflation penalties for generic drugs

    Today  . Per the legislation, generic drugs will have to pay an additional rebate on top of the basic rebate. ... As a result, 340B prices for generic drugs may be lowered as Medicaid URAs become higher.

More from intelligence
Approximately 1 fully matching, plus 29 partially matching documents found.

Latest appointments

  • Elite Pharma names Actavis VP as CEO Elite Pharma names Actavis VP as CEO

    These include 12 generic drugs already approved by the US Food and Drug Administration (FDA) but are yet to be marketed. ... An additional generic product is under review. “Nasrat has broad experience in both branded and generic pharmaceuticals as well

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics